Retrophin, Inc. (RTRX)
| Market Cap | 1.24B |
| Revenue (ttm) | 194.03M |
| Net Income (ttm) | -78.07M |
| Shares Out | 50.93M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Nov 18, 2021 |
| Last Price | $24.25 |
| Previous Close | $24.25 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 24.57 |
| Day's Range | 24.01 - 24.74 |
| Day's Volume | 378,991 |
| 52-Week Range | 8.98 - 24.96 |
News
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare...
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in Novem...
Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21
Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of...
SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement eq...
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with foc...
Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021
Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of...
Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Suc...
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price ...
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, s...
Retrophin's (RTRX) CEO Eric Dube on Q1 2020 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board
Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.
Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021
SAN DIEGO, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORD...
Retrophin, Inc. (RTRX) CEO Eric Dube on Q4 2019 Results - Earnings Call Transcript
SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Top Ranked Momentum Stocks to Buy for November 7th
The healthcare sector seems to be least affected by a protracted U.S.-China trade war.
Retrophin, Inc. (RTRX) CEO Eric Dube on Q3 2019 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 22.73% and -2.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
Retrophin had two assets disappear from its pipeline this year.
SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on qu...
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly ...
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare...
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
Find out how earnings and other factors hit these stocks.
Retrophin's PKAN drug candidate missed the mark in a late-stage trial.
Retrophin stock collapsed to a three-year low Thursday after the biotech company's treatment for a rare nervous system disease failed in a Phase 3 test. The drug missed two key goals.
Retrophin Inc (NASDAQ: RTRX) shares were plummeting Thursday following an adverse clinical readout from the company.
Shares of Retrophin Inc. RTRX, +1.81% plunged 26% toward a 3 1/2-year low in premarket trading Thursday, after the biopharmaceutical company said a phase 3 trial of its treatment for pantothen...
FORT Study did not achieve its primary or secondary endpoints
Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.
Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2019 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of -48.72% and 4.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
About RTRX
Retrophin, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC,... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Eric Dube | Employees 221 |
| Stock Exchange NASDAQ | Ticker Symbol RTRX |
Financial Performance
In 2019, Retrophin's revenue was $175.34 million, an increase of 6.75% compared to the previous year's $164.25 million. Losses were -$146.43 million, 42.6% more than in 2018.